Drug intelligence / Profile preview

simmitinib + irinotecan liposome

Development stage: Unknown
Lead developer: Ipsen
Modality: Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Classical Binding Small Molecules → Small Molecules
Administration: Intravenous

Overview

Simmitinib + irinotecan liposome is a combination therapy consisting of simmitinib (details on this agent are not available in the provided sources or current literature) and irinotecan liposome. Irinotecan liposome is a nanoliposomal formulation of the topoisomerase I inhibitor irinotecan, encapsulated within a lipid bilayer vesicle. This formulation prolongs circulation time and enhances tumor accumulation via the enhanced permeability and retention effect. Irinotecan and its active metabolite SN-38 inhibit topoisomerase I by binding to the topoisomerase I–DNA complex, preventing repair of single-strand DNA breaks during replication, leading to double-strand DNA damage and cell death. The primary indication for irinotecan liposome (Onivyde) is metastatic pancreatic cancer, typically in combination with other agents such as fluorouracil and leucovorin[1][3][4][7]. The developer/manufacturer for Onivyde is Ipsen Biopharmaceuticals[5][7].

Brand names: Onivyde
Other names: MM-398MM398MM 398PEP02PEP-02PEP 02nal-IRI

Targets

TOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on simmitinib + irinotecan liposome.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on simmitinib + irinotecan liposome.

Explore the full profile